


DC

**APPLICATION OF RECOMBINANT DNA TECHNOLOGY  
IN  
FRAGILE -X SYNDROME**



THESIS  
SUBMITTED IN PARTIAL FULFILMENT FOR THE  
DEGREE OF M.D. HUMAN GENETICS

*Kamal* BY  
**ALICE K. TAMMAM ABD EL-ALEEM**  
M.B., B.CH  
M.Sc. HUMAN GENETICS

116.042

A. 15

53327

SUPERVISED BY

**Prof.Dr. Mohamed A. Awadalla**  
Prof. of Pediatrics & Genetics  
Faculty of Medicine  
Ain-Shams University

*M. Awadalla*

**Prof.Dr. Samia A. El-Temtamy**  
Prof. of Human Genetics  
Human Genetics Departement  
National Research Center

*Samia A. El-Temtamy*

**Dr. Jörg Schmidtke**  
Prof. of Human Genetics  
Institute of Human Genetics  
Medizinische Hochschule Hannover, Germany

*Jörg Schmidtke*

**Prof. Dr. Mustafa K.El-Awady**  
Prof. of Biochemical & Molecular Genetics  
Human Genetics Departement  
National Research Center

*Mustafa K. El-Awady*

*Karam*  
**Assistant Prof. Dr. Karam Abd El-Aleem**  
Assistant Prof. of Human Genetics  
Faculty of Medicine  
Ain-Shams University



1995

*Handwritten signatures and notes at the bottom right, including '1995' and 'Genetic Research Center'.*

## ACKNOWLEDGMENT

I would like to express my sincerest gratitude to Prof. Dr. Mohamed A. Awadallah, prof. of Pediatrics, Faculty of Medicine, Ain-Shams University for supervising this work and for his continuous kind guidance . I do want to thank him for the support he always offers.

I would like to express my recognition to Prof.Dr. Samia A. El-Temtamy, Prof.of Human Genetics , National Research Center for suggesting the point of the Thesis and for her enlightening supervision . I am deeply grateful to her for the generous cooperation she always offered.

I am grateful to Prof. Dr. Jörg Schmidtke , Prof. and Head of Institute of Humangenetics , MHH for the good chance he gave it to me to learn the basic techniques in molecular biology and to apply them in my work under his supervision I feel truly indebted to him because of the sound atmosphere he is creating in the institute , that the young researcher find the freedom in thinking and in the way of performing their individual work . He never said no for the application of a new technique or for the several times repetition of an unsuccessful experiment. I liked his way and I found it exceptional. I want to thank him for his instructions in reviewing the Thesis.

I wish to thank Prof. Dr. Moustafa El-Awady , Prof. of biochemical and molecular genetics , National Research Center for his interest , valuable instructions and supervision of my Thesis .

Thanks to Dr. Karam Abd El- Aleem , Assistant Prof. of Human Genetics , Faculty of Medicine, Ain-Shams University for supervising my Thesis .

H, Afifi

Thanks to Dr. Hanan Hussny , Lecturer of Human Genetics , National research Center for her help especially in the collection of some of the blood samples from Egyptian patients.



I wish to express my thanks to all my colleagues in the IHG , MHH especially Dr. Manfred Stuhrman who was my direct supervisor , he had helped me a lot and accepted my mistakes. Dr. Ingolf Böhm , the first one who learned me the A B C in molecular work and I did with him the first successful non-radioactive PCR experiment . Herrn Wolfgang Künau , he offered me a lot of his technical experience, his assessment was continuous during the two and half year that I spend it in the IHG MHH.

Many Thanks for Herrn Frank Schnieders , Frau Andria Weimann , Frau Tania Vogel,& Dr. Sybila Jakubiczki for their generous help and continuous support .

## **Contents**

page

- List of Intials and File Numbers for The Analysed Cases.
- List of Tables.
- List of Figures.
- List of Abbreviations.

<b>1- Introduction .....</b>	<b>1</b>
<b>2- Aim of The Study .....</b>	<b>4</b>
<b>3- Review of Literature .....</b>	<b>5</b>
<b>3.1 Molecular Characterisation of The Fragile-X MR Syndrome.....</b>	<b>5</b>
<b>3.2 FRAXA / Clinical Overview .....</b>	<b>20</b>
<b>3.3 Cytogenetic Expression of Fragile-X Chromosome .....</b>	<b>23</b>
<b>3.4 Molecular Characterisation of FRAXE MR Syndrome .....</b>	<b>25</b>
<b>4- Material and Method .....</b>	<b>26</b>
<b>5- Results .....</b>	<b>60</b>
<b>6- Discussion .....</b>	<b>118</b>
<b>7- Summary and Recomendations .....</b>	<b>136</b>
<b>8- References .....</b>	<b>139</b>
<b>9- Appendix .....</b>	<b>151</b>

**Arabic Summary**

*Names' initials & file number corresponding to the given case number*

**Group A :**

*Egyptian cases:*

<i>Family No.</i>	<i>Pedigree No.</i>	<i>Initials</i>	<i>File No.</i>
1	II.2 III.4 III.3	mother of SF SF AF	3508
2	I.2 II.1 III.3 II.6	mother of AA AA MA Az A	4746
3	II.8 II.2	HF TF	2689
4	I.2 II.3 II.2 II.1	RH AH HH YH	1750
5	II.2 III.3 III.2	mother of A El A El Y El	
6	I.2 II.5	mother of SS SS	4640
7	I.7 III.4	mother of A Eb A Eb	6597
8	II.1	Kh Ab	2750

***German cases :***

<i>Family No.</i>	<i>Pedigree No.</i>	<i>File No.</i>
9	II.2	922
	III.3	923
	III.2	924
	II.3	1306
10	I.2	948
	II.2	950
	II.1	949
11	I.1	I
	II.2	II
	III.2	0
	II.3	840
	III.3	838
	II.4	833
12	I.12	972
	II.1	973
	II.2	974
13	II.3	1196
	II.1	Udo
	II.2	1197
14	II.4	1121
	III.3	1127
	II.5	1109
15	II.2	976
	III.2	975
	III.1	988
16	III.3	980
	IV.1	970
	III.2	982
17	III.5	1824
	III.6	1825
	II.2	642
	III.3	1822
	III.4	1815
	IV.1	606
	IV.2	508
	III.1	france

<i>Family No.</i>	<i>Pedigree No.</i>	<i>File No.</i>
18	No Pedigree	1028 1029
19	II.1 I.2	764 765
20	I.2 II.1	7 6
21	III.2 IV.2	17/88 f. 17/88 m.
22	I.2 II.2 III.1 III.2	18 19 22 23
23	II.2 III.3 III.2	12 5 4
24	I.2 II.1	9 8
25	I.2 II.2 III.2 IV.1 IV.2 III.3	8796 8797 8545 8546 8748 8798
26	II.6 II.5	9484 9339
27	III.3	9425



**Group B :**

***Egyptian Cases:***

<i>Case No.</i>	<i>Initials</i>	<i>File No.</i>
1	AR	5669
2	AEb	949
3	IAb	
4	RM	2711
5	NM	
6	Ksh	7027
7	NEI	
8	AA	6582
9	TEI	
10	AS	6549
11	FAb	
12	MEb	
13	FAb	6856
14	FN	886
15	AN	
16&17		6800
18&19		6801
20&21		6603
22&23		5948

*German cases :*

<i>Case No.</i>	<i>File No.</i>
1	22/92
2	115
3	273/92
4	269/92
5	301/92
6	348/92
7	151
8	Höpack
9	311
10	431
11	700
12	719
13	695
14	704
15	455
16	457
17	456
18	968
19	969
20	918
21	919
22	920
23	20
24	21
25	1036
26	1016
27	1124
28	1152
29	1061
30	913
31	641
32	771
33	776
34	759

## List of Tables

	page
Table (1a): Genetic , Cytogenetic and Main Clinical Features in 11 Egyptian Affected Individuals (9 males & 2 females) with The Fra-X Full Mutation. ....	67
Table (1b): Expression of Fragility and Main Clinical Features in 11 Egyptian Individuals With The Fra-X Full Mutation. ....	69
Table (2): Genetic , Cytogenetic and Main Clinical Features in The Two Egyptian Individuals Who Were Fra-X positive on Cytogenetic Analysis and Showed Neither FRAXA Nor FRAXE Mutation. ....	70
Table (3a): Genetic , Cytogenetic and Main Clinical Features in 26 German Patients (20 males & 6 females) With Fra-X Full Mutation. ....	71
Table (3b): Expression of Fragility and Main Clinical Features in 26 German Individuals With The Fra-X Full Mutation. ....	76
Table (4): Genetic , Cytogenetic and Main Clinical Features in Cases of Group B, Whose Cytogenetic Results Were Negative or Not Done and Proved to Carry the Typical Fra-X Mutation. (one Egyptian and 6 German Cases). ....	77
Table (5): Genetic , Cytogenetic and Main Clinical Features in Two German Male Carriers of Premutation Who Belong to Group B. ....	79
Table (6): Genetic , Cytogenetic and Main Clinical Features in 12 Egyptian Probands of Group B in Whom the Typical Fra-X Mutation Was Not Found. ....	80
Table (7): Percentage of Cytogenetic Expression and Range of Full Mutation in 10 Egyptian Patients With Fra-X Mutation. ....	83

Table (8): Percentage of Cytogenetic Expression and Range of Full Mutation in 13 German Patients With Fra-X Mutation. ....	84
---	----

## List of Figures

	<b>Page</b>
Figure (1): Intron / exon distances of FMR1. ....	7
Figure (2): Analysis of FMR1 protein in lymphoblastoid cell lines of males carrying normal or mutated alleles. ....	11
Figure (3): Separation of StB12xx ( 1.7 kb ) from the plasmid ( 2.9 kb ) , after XhoI digestion , through 1 % LMP agarose. ....	44
Figure (4): Dig-labeled genomic probes StB12.3 & oxE 20 via PCR amplification....	44
Figure (5a): Electrophoretic separation of well digested genomic samples. ....	47
Figure (5b): Electrophoretic separation of incompletely digested genomic samples...	47
Figure (6): Diagrammatic representation of the Southern blotting technique. ....	48
Figure (7): Diagrammatic representation showing the principle of non-radioactive chemiluminescence detection . ( from Boehringer Mannheim ) ....	50
Figure (8): Schematic representation of normal & mutated restriction fragments detected by probe StB12.3 . ....	61
Figure (9): Map of restriction sites & probes used in the direct DNA diagnosis of the fragile X syndrome. ....	61
Figure (10): Restriction map across the FRAXE region. ....	65
Figure (11): Pedigree symbols. ....	85
Figures (12-49): Families Pedigrees. ....	86 - 105

Figures (50 & 51): Non - radioactive detection of normal , premuta full mutated using the PCR agarose assay and genomic Southern blot with probe StB12.3, EcoRI/EagI double digest. ....	108, 111
--	----------

## List of Abbreviations

APS	Ammoniumperoxodisulfate
ATP	Adenosine triphosphate
bp	base pair
C	Cytosine
cDNA	complementary DNA
CTP	Cytosine triphosphate
CGG	Cytosine Guanine Guanine
C.V.S.	Chorionic Villus Sample
d ATP	deoxy Adenosine triphosphate
d CTP	deoxy Cytosine triphosphate
d GTP	deoxy Guanosine triphosphate
d TTP	deoxy Thymidine triphosphate
d UTP	deoxy Uridine triphosphate
DNA	deoxy ribonucleic acid
Dig.	Digoxigenin
DMSO	Dimethylsulfoxide
EDTA	Ethylendiamintetraacetat
g	gram
H <sub>2</sub> O	Water
HGD	Human Genetics Departement
hn RNA	heterogeneous nuclear ribonucleic acid
IHG	Institute of Human Genetics
Kb	Kilobase
KD	Kilodalton
LMP-agarose	Low melting point agarose
L/V/I-G	Leucine/valine/Isoleucine-Glycine
mRNA	messenger RNA
M-B	Martin-Bell syndrome
MCS	Multiclonal sites ( in plasmid vector )
MR	Mental Retardation
MHH	Medizinische Hochschule Hannover
NTM	Normal Transmitting Male